摘要
目的探讨低分子肝素联合米力农对慢性肺源性心脏病急性加重期患者的疗效。方法选择2010年1月～2012年1月来我科就诊的COPD合并肺源性心脏病患者68例,均为急性加重期,分为观察组和对照组各34例。两组均予吸氧,控制感染,止咳平喘,改善心肺功能,纠正水电解质失衡及对症支持等常规治疗,观察组同时予以低分子肝素联合米力农治疗,比较两组的疗效及分别记录两组患者治疗前、治疗后pH,PO2,PCO2的变化情况。结果观察组34例患者治疗后的总有效率达94.1%,对照组34例患者治疗后的总有效率达79.4%,对照组的总有效率明显低于观察组(P<0.05)。观察组治疗后的疗效明显优于对照组。观察组34例患者治疗后的pH、PO2、PCO2均分别较治疗前及对照组出现明显变化,对照组34例患者治疗后pH、PO2、PCO2均分别较治疗前明显改善,且观察组治疗后pH、PO2、PCO2较对照组改善更显著(P<0.05)。结论低分子肝素、米力农联合治疗慢性肺源性心脏病急性加重期疗效确切,值得临床推广应用。
Objective To investigate the efficacy of low molecular weight heparin and milrinone on patients with chronic pulmonary heart disease with acute exacerbation. Methods Sixty-eight cases were acute exacerbation of divid- ed into observation group and control group 34 cases. Both groups were treated oxygen, infection control, cough and asthma, improved heart and lung function, correct water and electrolyte imbalance and other conventional symptomatic and supportive treatment,the observation group at the same time was given low molecular weight heparin and milri- none, efficacy and pH, PO2, PCO2 changes were compared. Results The total effective rate of observation group was 94.1%,was significantly lower than the control group （P 〈 0.05）. After treatment, pH, PO2, PCO2 of the observation group compared with before treatment and control group had a distinct change,and the observation group＂ pH, PO2, PCO2 after treatment compared with pre-treatment significantly improved, improved than the control group （P 〈 0.05）. Conclusion The low molecular weight heparin milrinone combination therapy of chronic pulmonary heart disease with acute exacerbation of efficacy, and it is worthy of clinical application.
出处
《中国现代医生》
2013年第18期68-69,共2页
China Modern Doctor
关键词
慢性肺源性心脏病
低分子肝素
米力农
急性加重期
Chronic pulmonary heart disease
Low molecular weight heparin
Milrinone
Acute exacerbation
